A tool for patients undergoing cancer treatment to self-report symptoms was associated with benefits regarding physical well-being and self-efficacy, according to a trial with results reported in the Journal of Clinical Oncology.
The phase 3 randomized trial (ISRCTN Registry Identifier: ISRCTN88520246) evaluated the use of the eRAPID online health reporting system for patients to self-report symptoms they experienced during chemotherapy treatment for cancer. The eRAPID tool also provided basic guidance to patients. In this study, patients were assigned to either usual care or use of the eRAPID system for 18 weeks, with weekly reporting of symptoms. Clinicians also participated in report evaluation and with providing feedback. The primary endpoint of the study was symptom control at 18 weeks based on a physical well-being score.
Participants included 508 patients and 55 clinicians. The average rate of patient compliance was 64.7%. Physical well-being was rated as significantly better for patients using eRAPID, compared with usual care, at both 6 weeks (P =.0280) and 12 weeks (P =.0395). At 18 weeks, however, there was no significant difference between groups for this measure (P =.6992).
At 12 weeks, clinically meaningful deterioration of physical well-being occurred less in patients using the eRAPID tool than in those given usual care (47% vs 56%, respectively). Self-efficacy at 18 weeks was rated as better among patients using the eRAPID tool (P =.0073), and health-related quality of life using the EQ-5D-visual analogue scale was also better for patients using the eRAPID tool (P =.0095).
“Online symptom monitoring with severity-tailored patient advice via the eRAPID system improved physical well-being and self-efficacy in a population of patients predominantly treated with curative intent, without increasing hospital workload,” the study investigators wrote in their report.
Disclosure: Multiple authors declared affiliations with or received funding from the pharmaceutical industry. Please refer to the original article for a full list of disclosures.
Absolom K, Warrington L, Hudson E, et al. Phase III randomized controlled trial of eRAPID: eHealth intervention during chemotherapy. J Clin Oncol. 2021;39(7):734-747. doi:10.1200/JCO.20.02015
This article originally appeared on Cancer Therapy Advisor